TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented ABI 0.5-0.9~* Ability to walk on treadmill~Exclusion Criteria:~* Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment~* Critical limb ischemia~* Known or suspected peripheral neuropathy, heel cord contracture and foot deformity~* Other conditions that limit walking, e.g. lung disease or arthritis~* Active coronary artery disease such as unstable angina, significant left main disease or three vessel coronary artery disease (\>70% stenosis, unprotected by grafts) or recent (\<2 months) myocardial infarction,~* BMI \> 40,~* Known contraindication to MRI (intracardiac pacer, defibrillator, certain intracranial aneurysm clips, intraocular or cochlear implants, claustrophobia, etc.)~* Allergy to lidocaine or xylocaine (local anesthetic)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Home exercise (Type: EXPERIMENTAL): Patients will undergo home exercise therapy under the supervision of the exercise laboratory
- No exercise (Type: NO_INTERVENTION): Patients will continue with usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-proven CCE or clinically diagnosed CCE as assessed on the 3 following criteria : presence of one or more precipitating factors renal function deterioration in atherosclerotic patients ischemic changes of the extremities or demonstration of retinal embolism~* Severe CCE as defined by either acute renal failure (S creatinine \> 125 micromol/l and increase \> 25 % of baseline), or severe abdominal changes (hemorrhage, infarction, perforation or weight loss \> 5 % of body weight) or severe central nervous system neurological complication~Exclusion Criteria:~* CCE unproven, or restricted to one organ, or non-active contraindication to prednisone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prednisone (Type: EXPERIMENTAL): • Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
- placebo (Type: PLACEBO_COMPARATOR): Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with acute coronary syndrome (ST-depression in at least 2 leads \> 0,1 mV), or T-wave inversion, with or without elevated myocardial biomarkers (Troponin T oder I), together with typical clinical presentation), treated as follows:~* Acute percutaneous revascularization with stent implantation within 48 hours after symptom onset.~* Successful acute PCI (residual stenosis \< 30%, TIMI flow \> 2).~* Hemodynamic stability~* Age 18 - 80 years~* Written informed consent~* Active contraception in women of childbearing age~Exclusion Criteria:~* Patients with STEMI (ST elevation in 2 leads above 0,2 mV in lead V1, V2 oder V3 or above 0,1 mV in the other leads)~* Necessity of additional PCI in non-infarct vessel at the time of study therapy (multi-vessel PCI in the acute event is possible)~* Heart failure (LVEF ≤ 30 %).~* Arteriovenous malformation or aneurysms~* Active infection (C-reactive protein \> 10 mg/dl), or fever, or diarrhoea within the last 4 weeks~* Chronic inflammatory disease~* HIV infection or active hepatitis~* Neoplastic disease without documented complete remission within the last 5 years~* Recent stroke within the last 3 months~* Impaired kidney function (creatinin \> 2,5 mg/dl) at the time of treatment~* Significant liver disease (GOT \> 2x upper normal value or spontaneous INR \> 1,5.~* Hematopoetic disease (anaemia with Hb\< 8.5 mg/dl; thrombocytopenia \< 100.000/µl; splenomegaly~* Known allergies to Clopidogrel, Heparin or Abciximab~* History of bleeding disorder~* GI bleeding within the last 3 months~* Major surgery or trauma within the last 2 months~* Uncontrolled hypertension~* Pregnancy~* Mental disability~* Previous progenitor cell therapy~* Participation in a different clinical trial within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
- 2 (Type: PLACEBO_COMPARATOR): Intracoronary infusion of Placebo after NSTEMI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Histologically proven, invasive primary squamous, basaloid, or cloacogenic carcinoma of the anal canal, stage T1-4, N0-3~* No previous therapy for anal cancer.~* Age greater than or equal to 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2~* Adequate bone marrow, renal, and hepatic function defined as~  * Absolute neutrophil count greater than or equal to 1,000 cells/mm(3)~ * Platelet count greater than or equal to 100,000/mm(3)~ * Hemoglobin greater than or equal to 8mg/dL~ * Creatinine clearance \> 60 mL/min using Cockcroft-Gault formula~ * Bilirubin less than or equal to 1.5 times upper limit of normal (ULN) unless, during screening, the patient is receiving protease inhibitor therapy (i.e. indinavir, ritonavir, nelfinavir, and atazanavir) known to be associated with increased bilirubin: in this case total bilirubin less than or equal to 7.5 mg/dl and the direct fraction is less than or equal to 0.7 mg/dl.~ * White blood cell (WBC) greater than or equal to 3,000/microL~ * Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 3 times the upper limit of normal~ * International normalized ratio (INR) less than or equal to 1.5~* Patients of childbearing potential must be willing to use a medically effective means of birth control for the duration of treatment and six weeks after treatment.~* Patients must be willing and able to provide informed consent~EXCLUSION CRITERIA:~* Contraindications to radiotherapy such as a history of prior radiotherapy to the pelvis or a history of inflammatory bowel disease~* Prior malignancy except:~  * non-melanoma skin cancer~ * controlled Kaposi's Sarcoma (no chemotherapy for KS for 3 months, and no expected need for chemotherapy for the 12-month period of the study)~ * other malignancies with disease free period of at least 3 years~* Presence of metastatic disease (M1)~* Co-morbidity that in the estimation of the principal investigator would make the patient unable to tolerate treatment~* Pregnant or lactating females~* Human immunodeficiency virus (HIV) positive patients with cluster of differentiation 4 (CD4) \< 100 cells/mL AND ECOG performance status (PS) greater than 2.~* Dermatitis in the anticipated radiation treatment portal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1/Chemo + Radiation (Type: EXPERIMENTAL): Chemo + Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Divalproex vs. Lamotrigine for Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Bipolar I or Bipolar II disorder~* Prescription of divalproex (any formulation except for Depakene/valproic acid) or lamotrigine in the electronic pharmacy profile.~* Age 19 or older~* Demonstrated stability for at least 4 weeks on an adequate dose of each medication (at least 50mg/d lamotrigine or 15mg/kg/day divalproex).~* Treatment at the TVAMC for at least 6 months following the prescription of divalproex or lamotrigine.~Exclusion Criteria:~* Primary diagnosis of schizoaffective or schizophrenia during the evaluation period.~* Prescription of divalproex and lamotrigine given concurrently during the observation period.~* History of Dementia or cognitive disorders

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~1. Patients between the ages of 18-80 requiring an awake intubation for endotracheal intubation.~2. Ability to speak and understand English~Exclusion Criteria~1. Allergy to lidocaine~2. Emergent operative case~3. Therapeutic anticoagulation~4. Mouth opening less than 2 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Assessment of Superior Laryngeal Nerve Block Technique (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess Efficacy and Safety of a New Compression System in the Management of Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients or outpatients.~* Agreeing to wear a multilayer compression system throughout the study period.~* Presenting with an active venous leg ulcer: Duration between 1-24 months (whether a new ulcer or a recurrent ulcer); Surface area between 2-50 cm2; Venous, superficial or post-thrombotic ulcer confirmed by Doppler ultrasonography (dated within six months).~* With ankle circumference between 18-25 cm to allow the laying of the compression system.~* Able to follow the study instructions.~* Having read the information sheet and dated and signed the informed consent form.~* Covered by a health insurance system.~Exclusion Criteria:~* Scheduled surgery for the ulcer during the 16 weeks following inclusion.~* Clinical superinfected ulcer not controlled oral antibiotics.~* Malignant ulcer.~* Ulcer surface totally covered with dry fibrinous tissue or covered with black necrotic plaque on over 10% of its surface.~* Deep Vein Thrombosis within the last 3 months.~* Corticosteroids treatment (equivalent to more than 10 mg per day of prednisolone) ongoing or planned during the study.~* Radiotherapy, chemotherapy or immunosuppressive therapy ongoing or planned during the study.~* Erysipelas and lymphangitis.~* Lower extremity arterial disease or microangiopathy (Ankle Brachial Pressure Index \<0.8 or\> 1.3).~* Uncontrolled non-insulin dependent diabetes (HbA1c\> 8%).~* Insulin-dependent diabetes.~* Confined to bed.~* With any uncontrolled severe and progressive disease.~* With a known or suspected hypersensitivity to any of the components of the study devices.~* Who had participated in a previous clinical study within the past 3 months.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Kit Biflex (Type: EXPERIMENTAL): The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
- Profore (Type: ACTIVE_COMPARATOR): The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perception of the Risks of Alcohol and Individual Vulnerabilities in Young Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 45 years with moderate or severe alcohol use disorders~* Followed in addiction at Brest CHRU~Exclusion Criteria:~* Major from 18 to 45 years~* Current consumption of alcohol (multi-monthly)~* Follow-up in primary care or addictology in Brest

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with candidature for MFx surgery on the femoral articular surfaces (medial or lateral condyles or trochlear groove), with intact subchondral bone~* Subjects with moderate to severe pain in the target knee prior to surgery; average score greater than equal to (\>=) 4.0 over 7 consecutive days on numeric rating scale of pain intensity (completed within 30 \[+15\] days before surgery)~* Intraoperative inclusion criteria: Subjects with 1 or 2 focal chondral lesions per target knee, where peripheral debridement to healthy cartilage results in all of the following:~  * Each lesion has an area of \>= 1 square centimeter (cm\^2) and less than equal to (\<=) 4 cm\^2~ * Each lesion is \<= 6 millimeter (mm) in depth, as measured from the surrounding subchondral plate~ * Arthroscopic confirmation that each non-osteochondritis dissecans (OCD) lesion is between International Cartilage Repair Society (ICRS) Grades I and III (D); a Grade III non-OCD lesion is equivalent to an Outerbridge Grade IV lesion with minimal subchondral bone loss~* Other protocol-defined inclusion criteria could apply~Exclusion Criteria:~* Subjects with prior marrow stimulation treatment of the target knee, that is, MFx, micro-drilling, abrasion chondroplasty or cartilage repair including, but not limited to, autologous chondrocyte implantation (ACI), matrix/membrane autologous chondrocyte implantation (MACI), or osteochondral transplantation (autologous or allogeneic)~* Subjects with body mass index (BMI) of greater than 35 kilogram per square meter (kg/m\^2) at screening~* Malalignment of the target knee greater than 5 degrees as measured from the mechanical axis, as confirmed by alignment (long bone) X-ray images~* Subjects with clinical and/or radiographic disease diagnosis of the target knee joint including, but not limited to the following: generalized osteoarthritis (OA), rheumatoid arthritis, or avascular necrosis~* Subjects who have any contraindication to MRI or gadolinium-based or iodinated contrast agents according to the site's standard practice guidelines~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sprifermin (AS902330), 30 mcg (Type: EXPERIMENTAL): None
- Sprifermin (AS902330), 100 mcg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alternative in Beta Blocker Intolerance: The ABBI Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 21~* Male or female who is post-menopausal or not pregnant and using an approved contraceptive regimen~* Previous beta blocker use and intolerant of beta blocker~Exclusion Criteria:~* Systolic blood pressure \< 100 mmHg unless another blood pressure medication is stopped at the time of study entry~* Hospitalized for heart failure within the past 4 weeks~* Bradycardia with a heart rate \< 60~* Heart block greater than first degree~* History of sick sinus syndrome (unless a permanent pacemaker is in place)~* History of severe hepatic or renal dysfunction; serum Creatinine \> 2.0 or Amylase \> 3x normal~* Use of CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)~* Ingestion of investigational drug within the past 30 days

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: EXPERIMENTAL): Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient has been implanted (primo implantation or replacement) with an ICD model PARADYM VR 8250, DR 8550, CRT 8750, CRT 8770 models or any similar or higher range device~* ATP Auto-switch function is programmed ON~Exclusion Criteria:~* Presence of a contra-indication to the ICD therapy~* Life expectancy less than 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paradym VR, DR and CRT models (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep and Activity Monitoring After Thoracic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* undergoing thoracic surgery at Mayo Clinic Rochester~* expected to stay in hospital for at least 4 days~* signed consent form~Exclusion Criteria:~* Unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible for inclusion in the study will be symptomatic snoring children \>2 years of age and \< 10 years of age, who snore and have an apnea hypopnea index (AHI) \>2/hrTST (hour total sleep time), and in whom T\&A is therefore contemplated. Also among these, we will include children referred for evaluation for snoring who have a history of allergic rhinitis.~Exclusion Criteria:~* Exclusion criteria will include: Hypersensitivity to montelukast, immunodeficiency or immunosuppressant therapy, craniofacial, neuromuscular, syndromic or defined genetic abnormalities, acute upper respiratory tract infection, systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the study, and children who already had adenotonsillectomy. In addition, children chronically receiving oral antihistamine preparations or nasal decongestants will be required to continue using these medications throughout the duration of the study. Patients receiving immunotherapy will continue on the same regimen without escalation of dose and frequency throughout the duration of the study. In addition, patients with severe OSA who in the opinion of their treating physicians require early surgical intervention for their OSA will be excluded from eligibility to the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues